• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    3/22/24 4:05:23 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    false 0001641631 0001641631 2024-03-20 2024-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 20, 2024

     

    BEYOND AIR, INC

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38892   47-3812456
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Address of principal executive offices)

     

    (516) 665-8200

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    ☐ Emerging growth company

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On March 20, 2022, Beyond Air, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors, including certain directors and officers of the Company, (the “Purchasers”) pursuant to which the Company sold, in a registered direct offering, an aggregate of (i) 9,638,556 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”); and (ii) 9,638,556 common stock purchase warrants (the “Common Stock Warrants”) to purchase up to 9,638,556 shares of Common Stock (the “Common Stock Warrant Shares”). The combined offering price per Share and accompanying Common Stock Warrant is $1.66. Subject to certain ownership limitations, each Common Stock Warrant is immediately exercisable upon issuance at an exercise price of $2.25 per share and expires three years from the date of issuance.

     

    The Shares, Common Stock Warrants and Common Stock Warrants Shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-262311), which was declared effective by the Securities and Exchange Commission (the “SEC”) on February 1, 2022, as supplemented by a prospectus supplement and accompanying base prospectus dated March 20, 2024 filed with the SEC on March 22, 2024 pursuant to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

     

    The Securities Purchase Agreement contained customary representations and warranties. The offering closed on March 22, 2024.

     

    On March 20, 2024, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. (the “Co-Placement Agents”) as the co-placement agents in connection with the offering. Pursuant to the terms of the Placement Agency Agreement, the Co-Placement Agents agreed to use their reasonable best efforts to arrange for the sale of the securities in the offering. As compensation to the Co-Placement Agents, the Company paid the Co-Placement Agents a cash fee of 7% of the aggregate gross proceeds raised in the offering and the reimbursement of certain expenses and legal fees.

     

    The Company received net proceeds of approximately $14.6 million from the offering, after deducting the estimated offering expenses payable by the Company, including the Co-Placement Agents fees. The Company intends to use the net proceeds from the offering to fund commercial sales development, research, working capital and other general corporate purposes.

     

    In addition, under the Securities Purchase Agreement, until 90 days after March 22, 2024, subject to certain exceptions, neither the Company nor any of its subsidiaries shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock equivalents or (ii) file any registration statement or amendment or supplement thereto.

     

    In addition, from the date of the Securities Purchase Agreement, the Company has agreed not to enter into variable rate transactions (as defined in the Securities Purchase Agreement) for a period of six (6) months from the closing of this offering, subject to certain exceptions.

     

     
     

     

    The Securities Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.

     

    The form of Placement Agency Agreement, Securities Purchase Agreement and Common Stock Warrant, are filed as Exhibits 1.1, 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The above descriptions of the terms of the Placement Agency Agreement, Securities Purchase Agreement and Common Stock Warrant are qualified in their entirety by reference to such exhibits.

     

     

     

    Item 8.01. Other Events.

     

    On March 22, 2024, the Company issued a press release announcing the pricing of the offering. A copy of the press release announcing this matter is filed as Exhibit 99.1 to this Report and is incorporated by reference into this Item 8.01.

     

    Item 9.01. Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    1.1   Form of Placement Agency Agreement dated March 20, 2024, by and between Beyond Air, Inc. and Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd.
    4.1   Form of Common Stock Warrant
    5.1   Opinion of Sichenzia Ross Ference Carmel LLP
    10.1+  

    Form of Securities Purchase Agreement dated March 20, 2024, by and between Beyond Air, Inc and the Purchasers

    23.1   Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1)
    99.1   Press Release, dated March 20, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    + Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.

     

     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BEYOND AIR, INC.
       
    Date: March 22, 2024 By: /s/ Steven A. Lisi
      Name: Steven A. Lisi
      Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

     

     

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

    4/1/25 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

    First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

    3/24/25 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

    The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

    12/3/24 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    2/17/26 4:58:35 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    2/17/26 6:47:48 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    2/13/26 4:15:41 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

    Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

    12/1/21 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

    GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

    6/14/22 4:30:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care